Copilot said:
biomodal is proud to sponsor Grand Challenges in Parkinson’s Disease 2026, a premier forum uniting leading researchers, clinicians, and people with Parkinson’s to explore the latest advances in disease biology and therapeutic development. This year’s theme, From Brain Pathology to Biological Intervention, highlights new insights into alpha-synuclein pathology, early detection, and emerging therapeutic opportunities that are shaping the future of Parkinson’s research.
Meet biomodal at our table
Stop by to talk with Brett Evans, Territory Account Manager, about the technology that delivers genome and epigenome data in a single workflow.
Distinguish 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) together with all 4 canonical bases to measure multiple modes of biology from a single low-input DNA sample in a single experiment. The 6-base genome enables multidimensional DNA methylation analysis for biomarker discovery to gain transformative insights into current and future states of disease.
Take first look at biomodal’s newly launched duet mosaic™ family, new workflows for cfDNA and liquid biopsy research that combine genetic, epigenetic, and fragmentomic information from the same molecules, including short, damaged fragments other workflows may miss.
Come find the biomarkers you’ve been searching for and finally, see it all.